Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 27,000 shares at $24.45 ($661K) on 2026-10-01, disclosed to the SEC on 2026-10-05.
Scheduled sale ($661k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.45 | 26,400 | $646K | 97.7% |
| 2 | $25.32 | 600 | $15K | 2.3% |
| Total | $24.47 avg | 27,000 | $661K | 100% |
| Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |
| TNGX | SELL | 2026-05-05 | $573K | — | Filing → |